Amiodarone and breast feeding

An infant was born at 33+2 weeks gestation by caesarean section after an in utero diagnosis of fetal ascesis and tachycardia. The mother had received treatment during pregnancy with flecainide, amiodarone, and propranolol. The amiodarone was prescribed initially at 200 mg three times a day and was reduced to twice a day after 11 days.

The mother was keen to breast feed the baby. In previous reports of amiodarone and breast feeding, amiodarone treatment was for a maternal indication and hence continued post partum. In this case, the amiodarone treatment stopped at delivery. However, because of the long terminal half life of amiodarone (about 50 days), it could take several months for the level to fall. As one of the adverse effects of amiodarone is thyroid toxicity, the baby’s thyroid function was assessed and found to be normal. A decision was made to allow the mother to breast feed, and the baby was closely monitored.

Breast milk was sent for analysis to determine the amiodarone level on days 5, 11, 18, and 25. It had increased on day 11 (2.1 mg/l) compared with day 5 (0.6 mg/l). This may be due to changes in composition of the milk. We do not know at what time of day the milk was expressed or whether the sample was taken at the beginning or the end of the feed. The fat content of the milk was likely to be greater after 11 days than after 5 days, which may affect the distribution of amiodarone. McKenna et al described changes in amiodarone concentration in breast milk throughout the day. By 25 days, amiodarone was undetectable. Throughout this period the baby remained well and thyroid function was normal.

Although we would not recommend that breast feeding is necessarily safe for all babies exposed to amiodarone, this case illustrates that, in some circumstances, with close monitoring, breast feeding can be initiated.

C M Hall
Pharmacy Department, Royal Victoria Infnmary, Queen Victoria Road, Newcastle upon Tyne NE1 4LP, UK, catherine.hall@nuth.north.nhs.uk

K P B McCormick
Neonatal Unit, Royal Victoria Infnmary

References
3 Sanofi-Synthelabo. Summary of product characteristics. Cardarone X. Sanofi-Synthelabo, UK.

Reducing antibiotic use on the neonatal unit by improving communication of blood culture results: a completed audit cycle

It is common clinical practice to discontinue antibiotic treatment of asymptomatic babies if the blood cultures are negative at 48 hours. However, if blood culture results are only available during the normal working day, then antibiotic treatment of some babies may continue into the next working day. In our neonatal unit, blood culture results were routinely received from the microbiology laboratory via fax as a list every morning. Extra positive results would be telephoned through, if they became available, during the normal working day. Results could also be checked by the clinical staff telephoning the laboratory during “office hours”. This gave the potential for inadvertent prolongation of antibiotic courses for up to a day. In a previous study, McDonald et al found this to be a common occurrence. It is of concern because unnecessary antibiotic use may contribute to antibiotic pressure within the neonatal unit and may encourage the selection of drug resistant organisms.

We performed two audits into this problem within our neonatal unit. Our audit standard on each occasion was that antibiotics should be stopped at 48 hours, if blood cultures were negative, unless a decision to continue was clearly documented in the case notes. Babies with negative blood cultures were identified from the microbiology database. Each episode was classified into one of four groups: (a) antibiotics not started; (b) antibiotics stopped within 48 hours; (c) antibiotics given for more than 48 hours deliberately; (d) antibiotics given for more than 48 hours unintentionally.

The results are summarised in Table 1.

The first audit was conducted on 451 babies with negative blood cultures between January 1997 and December 1998. We were able to collect complete data from case notes and drug charts for 376 (83.4%) of these blood cultures. We found that the audit standard was not met in 144/376 (38.3%). The median (range) duration of antibiotic treatment for each baby was 60 (16.9–332) hours.

The blood culture analyst in use in our laboratory (BacT/Alert Microbial Detection System; Organon Teknika Corporation, Durham, North Carolina, USA) tests for bacterial growth every 10 minutes and communicates the blood culture status (positive or negative) to a computer. After our initial audit, we established a computer link between the blood culture analyst and the neonatal unit. This allows the clinical staff to check the status of any blood culture in the analyser in real time, 24 hours a day.

The second audit was performed on babies with negative blood cultures between May 2000 and August 2000. Two hundred negative blood cultures were identified. Complete data were available for 179/200 (89.5%). The audit standard was not met in only 20/179 (11.2%); p<0.001 compared with the first audit. The median (range) duration of treatment was reduced to 48 (1–182) hours (p<0.0001). There was an overall reduction of two doses of antibiotic per baby (from a mean of 8.8 to 6.8 doses per baby).

Overall, we estimated that we gave 21684 doses of antibiotics on the neonatal unit between January 1997 and December 1998. If the computer system had been in operation during this period, we estimate that we could have reduced this by 16.2% to 18 169. We think that this magnitude of reduction in antibiotic pressure on the neonatal unit is worth achieving.

M A Jardine, Y Kumar, S Kausalya, S Harigopal, J Wong, A Shivaram, T J Neel, C W Yoxall
Correspondence to: Dr Yoxall, Liverpool Women’s Hospital, Crown Street, Liverpool L8 7SS, UK, Bill.Yoxall@wkrh.nwest.nhs.uk

Table 1 Reduction in unintentional antibiotic use over 48 hours after introduction of real time availability of blood culture status by a computer link between the blood culture machine and our neonatal unit

<table>
<thead>
<tr>
<th>Results</th>
<th>No antibiotics started</th>
<th>Antibiotics stopped after &gt;48 h</th>
<th>Antibiotics continued for &gt;48 h</th>
<th>Antibiotics continued &gt;48 h unintentionally</th>
</tr>
</thead>
<tbody>
<tr>
<td>First audit</td>
<td>25 (6.6%)</td>
<td>132 (35.1%)</td>
<td>75 (19.9%)</td>
<td>144 (38.3%)</td>
</tr>
<tr>
<td>Second audit</td>
<td>15 (8.4%)</td>
<td>117 (65.4%)</td>
<td>27 (15.1%)</td>
<td>20 (11.2%)</td>
</tr>
</tbody>
</table>
References


Swaddling and heat loss

The letter of Hawkes et al. raises the important issues of swaddling and temperature on admission to the neonatal unit. Besch et al. carried out a limited comparison of different swaddling materials and found a transparent plastic bag together with radiant heat to be effective in preventing heat loss in infants over 2 kg. Following a report in the literature, we have begun swaddling all preterm infants < 1000 g in a thin plastic wrap. The wrap is preheated on a radiant warmer and the infant is immediately placed (unaided) on the plastic sheet, which is folded over to (but loosely) enclose the torso and extremities from the neck down. The infant is left in the wrap until transported to the neonatal unit and the temperature has stabilised in a humidified environment. The median temperature of the 19 < 1000 g infants admitted since wrapping was commenced was 36.7°C on arrival to the nursery compared with 35.5°C for the previous 86 unwrapped infants (p = 0.002, using Mann-Whitney U test). There were no significant differences in birth weight, gestational age or Apgar scores between the groups.

Although our experience is in smaller preterm infants (who are more prone to hypothermia), the results are in keeping with those of Vohra et al, who studied infants < 32 weeks.1 We now plan to wrap all preterm infants < 1500 g.

The plastic wrap is likely to be more effective than towels because of reduction in evaporative heat loss and because it allows observation of the infant. However, the plastic wrap is unlikely to significantly reduce radiant heat loss, so an additional heat source is essential for preterm infants. Some form of head swaddling is also important and needs further study. Aluminum foil may reduce evaporative, convective, and radiant heat loss but does not allow observation or radiant warming.

It appears there are many aspects of swaddling that require further investigation.

M P Meyer
Neonatal Paediatrician, Neonatal Unit, KidzFirst, Middlemore Hospital, Auckland, New Zealand and the University of Auckland; m.meyer@middlemore.co.nz

Preventing hypothermia at birth in preterm babies: a cost of overheating some?

In the Epicure study, the odds ratio of death before discharge for babies whose temperature on admission to the neonatal unit was > 35°C was 0.58 (95% confidence interval (CI) 0.39 to 0.85) compared with those with lower temperatures.1 In 2001, we therefore introduced a policy of wrapping neonates < 30 weeks gestation in polythene bags at birth without first drying them. Temperatures on admission to the neonatal unit after the introduction of this policy were compared with those of historical controls of < 30 weeks gestation admitted unwrapped between 1996 and 2000. The admission temperatures were analysed by stepwise multiple regression against being “bagged” or not, time to admission to the unit, birth weight, gestation, mode of delivery, month of delivery, and maternal temperature.

Table 1 shows that, in the comparable groups, this rise of 0.35°C resulted in a significant reduction in incidence of hypothermia (< 35.5°C) in “bagged” babies. However, significantly more of them (12%) developed thermoregulatory problems after partialy after ischaemia.1 The technique of wrapping babies in polythene bags would seem to benefit very preterm babies, although we may yet have to learn to use it appropriately.

T Newton, M Watkinson
Neonatal Unit, Birmingham Heartlands Hospital, Birmingham, UK; michael.watkinson@heartsol.wmids.nhs.uk

References


Table 1 Incidence of hypothermia and hyperthermia in control babies and babies wrapped in polythene bags (study group)

<table>
<thead>
<tr>
<th>Control group</th>
<th>Study group</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number</td>
<td>230</td>
</tr>
<tr>
<td>Gestation (weeks)</td>
<td>27.5 (23–29)</td>
</tr>
<tr>
<td>Weight (g)</td>
<td>1020 (400–1900)</td>
</tr>
<tr>
<td>Number &lt;35.5°C</td>
<td>96 (42)</td>
</tr>
<tr>
<td>Number &gt;37.0°C</td>
<td>6 (12.5)</td>
</tr>
</tbody>
</table>

| Values are either median (range) or number (%). CI, Confidence interval. |

Technique for insertion of percutaneous central venous catheters in the newborn period

The use of percutaneous central venous catheters is of proven value for the provision of parenteral nutrition and intravenous drug treatment in neonates. They have become an integral part of the management of very low birthweight infants in most intensive care units.

At the Royal Children’s Hospital in Melbourne we used a plastic catheter, which has an external diameter of 0.6 mm and comes in a variety of different lengths (Epicutaneous catheter manufactured by Vygon; lengths 15, 30, and 50 cm; ref nos 2184.015, 2184.00, and 2184.005; cost AU$59). It is packaged with a metal 19 GA butterfly needle for use in insertion of the line.

This technique has some drawbacks.

(1) The 19 GA needle is difficult to pass directly into neonatal veins because of its large size.

(2) It can be difficult to appreciate “flash back” of blood into the metal needle.

(3) It is not possible to “flush” the needle to ensure correct positioning of the line as well as sterility of the vessel.

(4) It is not feasible to place femoral venous lines using this method.

We therefore use a method whereby the vein, using the Seldinger technique, is ultimately cannulated with a 20 GA catheter through which the slippage line can be inserted.

(1) The procedure should be carried out under optimal conditions using an aseptic technique. If the infant is already ventilated, we advocate the use of a muscle relaxant as well as adequate sedation. This is especially advisable for insertion of femoral venous lines.

(2) The vein is initially cannulated with a 24 GA (external diameter 0.7 mm) cannula. The sites most often used are the great saphenous vein at the ankle or knee joint, the femoral vein, the basilic or cephalic veins in the antecubital fossa, or, occasionally, the superficial temporal vein. A transilluminator or “cold light” inserted into the finger of a sterile glove can be used in locating deep veins as well as protecting the sterility of the field.

(3) A guidewire is then inserted through the cannula into the vein. We use a “duoflex spring wire guide”: diameter 0.45 mm, length 25 cm (duoflex spring wire guide manufactured by Arrow; product no AW-04018; cost
Umbilical granulomas: a randomised controlled trial

The Archimedes section has previously contained a brief section on the treatment of umbilical granulomas. We have now conducted a randomised controlled trial of the management of umbilical granulomas. The trial compared silver nitrate cautery with the use of alcoholic wipes at each nappy change (conservative management). The impetus for this work was a series of three burns to the anterior abdominal wall after silver nitrate cautery, seen in a single London hospital over a two year period.

The trial aimed to show equivalence between the two treatment modalities. On the basis of equal efficacy, we intended to change practice to conservative management. More than 40 infants were referred, but a large number of parents chose conservative management rather than randomisation. Difficulty in recruitment meant there were inadequate numbers to show statistical significance within the limited time span available.

The salient results were that two of three granulomas resolved over a three week period without cautery. Those infants whose granulomas did not resolve went on to treatment with cautery following a protocol that involved drying the area both before and after silver nitrate application, surrounding the umbilicus with white soft paraffin, and leaving the area exposed for 10 minutes after application. This resulted in resolution in all remaining cases without harm due to delay in treatment.

Table 1 Comparison between the outcomes for grade 3–4 intraventricular haemorrhage (IVH) in the three studies

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Murphy et al</th>
<th>MMC 1980s</th>
<th>MMC 1997–2001</th>
</tr>
</thead>
<tbody>
<tr>
<td>Grade 3–4 IVH (% of all &lt;1500 g)</td>
<td>79%</td>
<td>94%</td>
<td>29%</td>
</tr>
<tr>
<td>Death &gt;14 days</td>
<td>18/79 (23%)</td>
<td>29/94 (30%)</td>
<td>8/29 (28%)</td>
</tr>
<tr>
<td>PVD requiring treatment</td>
<td>34/61 (56%)</td>
<td>24/65 (37%)</td>
<td>11/21 (52%)</td>
</tr>
<tr>
<td>VP shunt/late death (% of PVD treatment)</td>
<td>18/8 (26/34=76%)</td>
<td>12/3 (15/24=63%)</td>
<td>6/1 (7/11=63%)</td>
</tr>
</tbody>
</table>

*Rate for all infants <35 weeks. **Rate for all deaths <30 days. MMC, Maine Medical Center; PVD, progressive ventricular dilatation; VP, ventriculoperitoneal.

References


Umbilical granulomas: a randomised controlled trial

The Archimedes section has previously contained a brief section on the treatment of umbilical granulomas. We have now conducted a randomised controlled trial of the management of umbilical granulomas. The trial compared silver nitrate cautery with the use of alcoholic wipes at each nappy change (conservative management). The impetus for this work was a series of three burns to the anterior abdominal wall after silver nitrate cautery, seen in a single London hospital over a two year period.

The trial aimed to show equivalence between the two treatment modalities. On the basis of equal efficacy, we intended to change practice to conservative management. More than 40 infants were referred, but a large number of parents chose conservative management rather than randomisation. Difficulty in recruitment meant there were inadequate numbers to show statistical significance within the limited time span available.

The salient results were that two of three granulomas resolved over a three week period without cautery. Those infants whose granulomas did not resolve went on to treatment with cautery following a protocol that involved drying the area both before and after silver nitrate application, surrounding the umbilicus with white soft paraffin, and leaving the area exposed for 10 minutes after application. This resulted in resolution in all remaining cases without harm due to delay in treatment.

On the basis of this work, we suggest a change in current practice to initial conservative management followed by cautery only when conservative treatment fails.

J Daniels
Homerton Hospital, London, UK
F Croog
Great Ormond Street Hospital, London, UK
R Wajed
Northwick Park Hospital, London, UK
M Meates
North Middlesex Hospital, London, UK

G Bayley
Bristol School of Anaesthesia, Bristol, UK

Correspondence to: Dr Bayley, Department of Anaesthetics, Bristol Royal Infirmary, Marlborough Street, Bristol, UK; kateandguy@hotmail.com

References


Comparison between the outcomes for grade 3–4 intraventricular haemorrhage (IVH) in the three studies

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Murphy et al</th>
<th>MMC 1980s</th>
<th>MMC 1997–2001</th>
</tr>
</thead>
<tbody>
<tr>
<td>Grade 3–4 IVH (% of all &lt;1500 g)</td>
<td>79%</td>
<td>94%</td>
<td>29%</td>
</tr>
<tr>
<td>Death &gt;14 days</td>
<td>18/79 (23%)</td>
<td>29/94 (30%)</td>
<td>8/29 (28%)</td>
</tr>
<tr>
<td>PVD requiring treatment</td>
<td>34/61 (56%)</td>
<td>24/65 (37%)</td>
<td>11/21 (52%)</td>
</tr>
<tr>
<td>VP shunt/late death (% of PVD treatment)</td>
<td>18/8 (26/34=76%)</td>
<td>12/3 (15/24=63%)</td>
<td>6/1 (7/11=63%)</td>
</tr>
</tbody>
</table>

*Rate for all infants <35 weeks. **Rate for all deaths <30 days. MMC, Maine Medical Center; PVD, progressive ventricular dilatation; VP, ventriculoperitoneal.
Do we need to assess the thyroid function in the infants of mothers with Hashimoto’s thyroiditis?

We read with interest the recent comprehensive review of neonatal thyroid disorders, which gave evidence-based answers to many important questions. The author recommended that all babies born to mothers with Hashimoto’s thyroiditis should be reviewed at 10 days to 2 weeks and a thyroid function test taken because infants may develop transient hypothyroidism or, very rarely, hyperthyroidism.

As paediatricians, in a hospital with a paediatric endocrine caseload similar to some tertiary centres and a subregional neonatal intensive care unit with local deliveries of 6000 per annum, we think that the potential benefits of this practice are difficult to justify. We do understand that such practice will help in identifying babies who may develop transient congenital hypothyroidism caused by maternal thyrotropin receptor blocking antibodies. However, the incidence of this form of hypothyroidism has been estimated to be 1 in 180 000 normal infants (2% of congenital hypothyroidism) and the majority of them will have raised thyroid stimulation hormone levels that can be detected by the current neonatal screening. Based on a simple calculation, in a unit of our size only one baby will be detected every 30 years. We feel that there would be major disadvantages if we are to adopt the author’s recommendation. Firstly, an extra hospital visit for babies and parents; secondly the need to bleed many healthy infants; and finally the potential for confusion and unnecessary anxiety. Until objective evidence emerges about the significance of subtle thyroid dysfunction in early life we feel that the current screening programme should not be extended.

A M Habeb
Paediatric Department, Hull Royal Infirmary; ahabeb@hey.nhs.uk

M Zubier, P Pairaudeau, V Mathew
Paediatric Department, Hull Royal Infirmary

References

CORRECTIONS

In the CD Review (Arch Dis Child Fetal Neonatal Ed 2003;88:F164) reviewed by C Wren, please note that the affiliation of the authors is published incorrectly. This should have read Royal Prince Alfred Hospital, Sydney. Also, the web address in the final paragraph is incomplete. The correct address is: http://www.cs.nsw.gov.au/rpa/neonatal/default.htm. The errors are much regretted.

The authors would like to acknowledge and apologise for an error in our article Socioeconomic status and preterm birth: New Zealand trends, 1980 to 1999. ED Craig, JMD Thompson, EA Mitchell (Arch Dis Child Fetal Neonatal Ed 2002;86:F142–F6).

Paragraph four in the Results section should read “Figure 2 summarises changes in preterm birth rates by Deprivation Index decile between 1980 and 1999. During this period rates rose from 5.2% to 5.9% among those living in the most deprived areas (a 13.5% increase), from 4.0 to 5.5% amongst those living in average areas (a 37.5% increase) and from 3.1% to 5.4% amongst those living in the least deprived areas (a 74.2% increase). Thus while in 1980 a marked social gradient in preterm birth existed, by 1999 this had diminished markedly.” Table 2 and table 3 are amended. These errors do not significantly change the reported trends in preterm birth or the interpretation of the findings previously published.

Table 2 Multivariate odds ratios for preterm birth by gestational age category and Deprivation Index decile; New Zealand singleton live births 1980, 1990, and 1999

<table>
<thead>
<tr>
<th>Year</th>
<th>NZDep Index</th>
<th>All preterm (n=51 711) OR*</th>
<th>20–27 weeks (n=2697) OR**</th>
<th>28–33 weeks (n=12 703) OR*</th>
<th>34–36 weeks (n=36 311) OR*</th>
</tr>
</thead>
<tbody>
<tr>
<td>1980</td>
<td>1</td>
<td>1.00</td>
<td>1.00</td>
<td>1.00</td>
<td>1.00</td>
</tr>
<tr>
<td>1980</td>
<td>5</td>
<td>1.15</td>
<td>1.08</td>
<td>1.16</td>
<td>1.15</td>
</tr>
<tr>
<td>1980</td>
<td>10</td>
<td>1.36</td>
<td>1.18</td>
<td>1.39</td>
<td>1.36</td>
</tr>
<tr>
<td>1990</td>
<td>1</td>
<td>1.30</td>
<td>1.31</td>
<td>1.21</td>
<td>1.33</td>
</tr>
<tr>
<td>1990</td>
<td>5</td>
<td>1.44</td>
<td>1.45</td>
<td>1.47</td>
<td>1.47</td>
</tr>
<tr>
<td>1990</td>
<td>10</td>
<td>1.63</td>
<td>1.66</td>
<td>1.52</td>
<td>1.67</td>
</tr>
<tr>
<td>1999</td>
<td>1</td>
<td>1.64</td>
<td>1.67</td>
<td>1.44</td>
<td>1.72</td>
</tr>
<tr>
<td>1999</td>
<td>5</td>
<td>1.76</td>
<td>1.91</td>
<td>1.53</td>
<td>1.84</td>
</tr>
<tr>
<td>1999</td>
<td>10</td>
<td>1.93</td>
<td>2.25</td>
<td>1.64</td>
<td>2.02</td>
</tr>
</tbody>
</table>

Multivariate analysis adjusted for gender, maternal age, parity, birth year, and birth year*decile, year*age, year*parity, decile*age, decile*parity.
*Odds ratios (OR) with reference category Deprivation Index decile 1, 1980.
**Odds ratios for the 20–27 week category did not reach statistical significance.

Table 3 The “social gradient in preterm birth”; risk of preterm birth amongst decile 10 women compared to decile 1 women (same year), New Zealand singleton live births 1980, 1990, and 1999

<table>
<thead>
<tr>
<th>Year</th>
<th>All preterm (n=51 711) OR*</th>
<th>20–27 weeks (n=2697) OR**</th>
<th>28–33 weeks (n=12 703) OR*</th>
<th>34–36 weeks (n=36 311) OR*</th>
</tr>
</thead>
<tbody>
<tr>
<td>1980</td>
<td>1.36</td>
<td>1.18</td>
<td>1.39</td>
<td>1.36</td>
</tr>
<tr>
<td>1990</td>
<td>1.26</td>
<td>1.27</td>
<td>1.25</td>
<td>1.26</td>
</tr>
<tr>
<td>1999</td>
<td>1.17</td>
<td>1.35</td>
<td>1.14</td>
<td>1.17</td>
</tr>
</tbody>
</table>

Multivariate analysis adjusted for gender, maternal age, parity, birth year, and birth year*decile, year*age, year*parity, decile*age, decile*parity.
*Odds ratios (OR) for preterm birth amongst decile 10 women compared to those in decile 1 for each particular year reflect the social gradient for that year.
**Odds ratios for the 20–27 week category did not reach statistical significance.
Late anaemia in Rh haemolytic disease

As it is clearly stated in the review by Gottstein and Cooke,1 we consider it unethical to withhold or delay high dose intravenous immunoglobulin (IVIG) treatment in infants with haemolytic disease of the newborn. Since the study we did in 1995,2 we have treated 129 patients with Cosmil’s positive haemolytic disease of the newborn, with the same method and had to resort to exchange transfusions only in three cases. On the other hand, late anaemia is a frequent problem in these cases, necessitating multiple blood transfusions, with well known complications.

The authors suggest that multiple doses of IVIG may reduce late anaemia. However, our observation in a limited number of cases is that, even multiple doses of IVIG are ineffective in preventing late anaemia. In an earlier unpublished study, we had shown that the erythropoietin levels were low in these infants. Therefore, we had conducted a double blind, randomised pilot study to investigate the effects of recombinant erythropoietin (rHEPO) in these patients.3 In this study, rHEPO was administered at a dose of 200 units/kg, subcutaneously, three times a week, starting at the 14th day of life and lasting for six weeks. This protocol reduced the number of erythrocyte transfusions significantly. With the impetus of this pilot study, we have used the same protocol for the subsequent 103 patients and the mean number of transfusions in this group was 1.5, with the majority of patients (55%) not needing any transfusions at all. There were no complications, including changes in neutrophil or platelet counts, and haemorrhagic or infectious complications. The administration of rHEPO to patients with haemolytic disease of the newborn, who had received IVIG early in life, not only decreases the infants’ exposure to multiple blood donors, but also diminishes the need for hospitalisation and hence the cost that is involved. Therefore, rHEPO treatment is a suitable alternative to erythrocyte transfusions in these infants.

Systematic review of intravenous immunoglobulin in haemolytic disease of the newborn

We read with interest the recent review of Gottstein and Cooke.1 Their systematic review of trials reporting treatment of infants with proven Rh and/or ABO haemolytic disease of the newborn (HDN) treated with high dose intravenous immunoglobulin (HDIVIG) and phototherapy, with phototherapy alone demonstrated that significantly fewer infants required exchange transfusion in the HDIVIG group. The authors point out that anti-D is the most common red cell antibody responsible for HDN. We have recently treated two children both of whom developed evidence of immune haemolysis due to anti-D antibodies acquired from IVIG.

The first patient, a 4 month old infant with Kawasaki’s disease, was treated with intravenous immunoglobulin (2g/kg) with immediate control of fever and irritability. Ten days later her disease became clinically active again and she was therefore given a second dose of IVIG (2g/kg from a different batch), which is a recognised therapeutic option.2 Her clinical condition again improved rapidly. A blood count two days after the second dose of IVIG showed that her haemoglobin; had fallen suddenly by 2g/dl to 6.4g/dl, the blood film showed spherocytes and the direct antiglobulin test was positive, evidence of immune haemolysis. Samples that were collected prior to the second dose of IVIG confirmed her blood group to be AB Rh D positive. The manufacturer of the IVIG investigated the batches used and reported that the IVIG used for the second dose contained anti-D. The second patient, a 12 year old boy with systemic juvenile idiopathic arthritis received a fifth dose of IVIG from the same batch. He was screened for evidence of haemolysis and his antiglobulin test was positive 14 days after treatment. He remained asymptomatic with no fall in haemoglobin.

IVIG is early maternal blood product not a drug; each batch is made from a pool of plasma collected from several thousand donors. Passive transfer of potentially significant red cell antibodies is a recognised hazard, reported in the company literature but only as a serological phenomenon, not as a clinical warning.

High dose intravenous immunoglobulin in haemolytic disease of neonates

It was encouraging to read article of Gottstein et al,1 on the use of high dose intravenous immunoglobulin (HDIVIG) in cases of haemolytic disease of newborns (HDN) with their conclusion showing the effectiveness of HDIVIG. I have the following observations to make with respect to implications on practice and future research.

Firstly, all the references mentioned were between three and ten years old.4 These trials did not take into consideration the irradiance of the phototherapy used, although they did observe the number of exchange transfusions performed. Presently, a combination of blue and white fluorescent light double surface phototherapy, with effective higher irradiances of 20–40 uW/cm2/nm, can practically eliminate the need for exchange transfusion, even in severe cases of HDN. Irradiance of phototherapy can be increased further by decreasing the distance between the phototherapy unit and the patient, especially with an undersurface phototherapy unit, keeping thermal and nursing issues under consideration.

Secondly, the authors did not address enterohepatic recirculation of bilirubin from the gut. Inexpensive measures can decrease the back entry of bilirubin from gut, like early enteral feeds, oral administration of agar agar, isabagol husk and so forth, and further reduce serum bilirubin levels. Further randomised controlled trials are required before administration of HDIVIG becomes routine in HDN. These trials should compare use of current effective phototherapy combinations with the
highest possible irradiance, agents that de-
crease enterohepatic recirculation of bilirubin
with or without HVIDIG, and the need for
exchange transfusion in HDN. They should al-
so address cost effectiveness and safety, con-
sidering the cost of HVIDIG in the developing
world.

G Gupta
Armed forces Medical College, Pune, India;
guptas-ip@hotmail.com

References
1 Gottstein R, Cooke RWI. Systematic review of intra-
venous immunoglobulin in haemolytic disease of the
2 Alpay F, Sarici SU, Okutan V, et al. High-dose intra-
venous immunoglobulin therapy in neonatal immune haemolytic
3 Dagaglu T, Ovari F, Samaci N, et al. High-dose intra-
venous immunoglobulin therapy for thalassaemia. J Int Med
4 Rübo J, Albrecht K, Lasch P, et al. High-dose intra-
venous immune globulin therapy for hyperbilirubinemia caused by B hemolytic
administration of high-dose intravenous
immunoglobulin in rhesus hemolytic disease. J Perinat Med
6 Rübo J, Wahn V, et al. Influence of high
dosage immunoglobulin therapy on
hyperbilirubinemia in rhesus hemolytic

Authors’ reply
We are grateful to our colleagues for their interest and responses to our paper. In response to Dr Ovaly’s comments, we agree that late anaemia can be a problem in babies who have intravenous immunoglobulin (IVIG), as is also demonstrated in our systematic review. Even when infants have received exchange transfusions (XTs) top up red cell transfusions may be required. In a recent local audit of XTs, 35% of babies received top up red cell transfusions after one or more exchange transfusions. During a five year period from 1998-2002, 27 babies with Rhessle, Kell, or ABO incompatibility had 28 XTs. Gestation ranged from 28 to 40 completed weeks. Of 26
infants for whom follow up data was avail-
able, nine (35%) had received top up red cell transfusions.
We read with interest Dr Ovaly and colleagues paper describing a double blind randomised controlled trial of subcutaneous recombinant human erythropoietin (rHEPO), and its use in this situation. We recently had a debate in our unit about whether or not it was better for a well twin to remain with its sibling in hospital until the latter was fit to be discharged. Our current practice is to keep the well twin in the special care baby unit until its twin is fit for discharge. The group who favoured separate discharge cited reduced risk of nosocomial infection, decreased costs, cot availability, and the possibility of settling into a routine with one twin at home as supportive factors for their argument. Those against separate discharge cited impaired bonding, breast feeding
difficulties, and transport issues as their reasons.

We took the discussion to the RCPCH and NICU-net email discussion groups and found no clear consensus. Our American colleagues routinely send multiples home separately and cite health insurance companies as a major factor in this decision. They find little problem with this arrangement. One opinion was split between the two camps. British doctors seemed to be in favour of asking the parents’ opinion, so we identified 10 sets of twins from the last three years who could have been sent home separately. We then sent their parents a questionnaire exploring their opinions; five (50%) were returned.

Most parents agreed that their twins were ready for discharge at different times and said that they would have preferred separate discharge. However, they believed that they had been given this option and had not taken it. They realise that this would have caused problems with visiting, feeding, and bonding with the remaining twin even although they all had their own transport. They did not think that having one twin home first would have helped them to adjust and settle into a routine. Their preferred option would have been to have roomed in with the well twin while the other twin stayed on the special care baby unit.

Our current practice is that we have an informed discussion with the parents when this situation arises. As one email respondent (a doctor and his other twins) wrote, ‘Having
up twins is full of decisions about when to pair them and when to split them up.’

J P Chapman, K Lange
James Paget Hospital, Lowestoft Road, Gorleston,
Norfolk NR31 6LA, UK

Correspondence to: Dr Chapman;
john.chapman@jpaget.nhs.uk

Role of serum peak levels of vancomycin in neonatal intensive care units

We would like to comment on the article by Tan et al.1 The purpose of measuring serum levels of a drug is either to monitor the toxicity of the drug or the therapeutic concentra-
tion for a particular condition. Emergence of infections with β-lactam-resistant Staphylococ-
sus epidermidis, Staphylococcus aureus, and Ente-
robacter sp, has led to the frequent use of van-
comycin in neonates. Vancomycin has historically had a reputation for toxicity. Many of its original adverse reactions, including ototoxicity and nephrotoxicity, were prob-
ably due impurities in the formulation. Now that a more purified form is available, these adverse reactions are uncommon. However, concomitant administration with aminogly-
cosides or other nephrotoxins may increase the risk of toxicity.1 Effective drug therapy is measured by response, not by achievement of a particular circulating drug concentration. Because the association between vancomycin peak concentrations and toxicity is poor, some have recommended measuring trough concen-
tration only2 as this study is clearly documenting, but others have suggested not measuring any concentrations in the majority of children with normal renal function.3,4 However, in critically ill premature neonates with poor glomerular filtration rate, prematu-

Jain
Southern Illinois University School of Medicine,
Springfield Illinois, USA; jeainsunil@hotmail.com

References

www.archdischild.com

Methaemoglobinemia with concurrent blood isolation of Saccharomyces and Candida

Saccharomyces boulardii is closely related to Saccharomyces cerevisiae and is used as a therapeutic agent, although some reports suggest pathogenicity. We present a case of neonatal sepsis with concurrent methaemoglobinemia, occurring after a brief period of treatment with S boulardii. A male infant was born at 30 weeks of gestational age by caesarean section because of intrauterine growth restriction and maternal hypertension. The baby was well apart from persistent gastrointestinal symptoms that hampered feeding and forced parenteral support. During the third week of life, administration of S boulardii (Codex DNB; half a capsule a day, equivalent to 2.5 x 10^9 organisms) was started in an attempt to prevent bacterial overgrowth. After four days of treatment, the baby developed symptoms suggesting sepsis and an unexplained methaemoglobinemia (methaemoglobin concentration = 16%). Codex was stopped and empirical antibiotic coverage, combined with age and full gastrointestinal function, was started. Blood cultures showed growth of S cerevisiae, which is susceptible to amphotericin B, in the absence of any clinical finding; again, the catheter tip was sterile. Methaemoglobin concentration was still abnormal (6.2%). Liposomal amphotericin B treatment was prolonged for a further six days and then discontinued. At this time, methaemoglobin levels were near normal (3%), and blood cultures were negative. The gastrointestinal symptoms resolved with age and full gastrointestinal function was achieved.

References
Neonatologists are not always directly involved in the intensive care of neonates as surgical patients. In my own case this has led to a slightly blinkered approach. I am very familiar with perinatal stabilisation of problems such as hyaline membrane disease, infection, and respiratory disorders. However, perinatal management, particularly of uncomplicated cases, and the mysteries of operative techniques have been beyond my reach. A book, with neonatologists within its scope, ideally with strong emphasis on presentation, embolus, and associations as well as describe the surgical options, would plug a significant gap in my knowledge.

With 97 chapters, typically under 10 pages each, this book certainly has breadth of coverage. Chapters typically deal with a problem such as chylothorax, subcutaneous emphysema, or necrotising enterocolitis and describe the authors’ perspective on management. There are numerous photographs, radiographs, and drawings in nice balance with the text. Editing to complement the “comprehensive description of operative techniques” left me wondering that such complicated operations could be written as such. The authors are drawn from all over the world, but the book’s style remains uniformly European.

The book begins with a series of chapters dedicated to general and theoretical aspects of the care of the high risk infants. These areas of overlap with standard neonatal texts are very variable and, from my perspective, also very interesting. Some could have been more up to date. It was also interesting for example to see a chapter on neonatal transport written by two paediatric surgeons rather than by neonatologists.

Some overlap is inevitable in a book like this. However, I would have preferred, for example, that there was more embryology in each surgical chapter or a more comprehensive introductory chapter. A well written chapter on ethics, from a purely neurosurgical perspective, would also be a space given to parenteral nutrition. The five sides dedicated to respiratory management of the newborn are very variable and, from my perspective, therefore recommend this book to fellow paediatricians, much as I would encourage surgeons and neonatologists to further develop collaboration in practice and in training.

S Oddie
Royal Victoria Infirmary, Newcastle upon Tyne
NE2 2PU, UK; s.oddie@ncl.ac.uk

Nestle nutrition workshop series: pediatric program, Vol 52: micronutrient deficiencies in the first months of life


Micronutrient deficiencies in the first few months of life may not keep you awake at night if you are working in the UK, and this book may not grab your attention straight away, but you should give it some consideration whatever your branch or specialty in paediatrics. The book is a collection of 16 papers, written by an international panel of experts, which are the proceedings of a workshop held in Dubai in October 2002.

Most of us will be familiar with the problems of iron deficiency in early infancy and the debate on the role of neonatal vitamin K administration, and, if pushed, many of us would be able to say something about the public health implications of maternal folic acid supplementation and prevention of neural tube defects. This book presents papers that provide thorough state of the art reviews of these subjects. The practice of most UK based paediatricians won’t frequently encompass micronutrient deficiencies outside of these aforementioned areas, but this book reminds us that, from a global perspective, nutritional deficiency problems are extremely prevalent. Vitamin A deficiency probably affects over 40% of the world’s children, and iodine deficiency affects over 10%, with salt iodination theoretically simple, but practically complicated. Iron deficiency is a truly global problem which affects at least one in three children worldwide.

Many of us might be surprised to learn that over 50% of children in China and Tibet have features of rickets (which is also a growing (sic) problem among certain groups in the UK), and the latest evidence on the benefits of zinc supplementation in the prevention and treatment of diarrhoea, and in promotion of linear growth from field trials in developing countries, is truly compelling. Because the book is really a series of presented papers, it is genuinely more readable than a textbook on the subject. A paper on the relation between micronutrients in pregnancy and early infancy and mental and psychomotor development, and on special micronutrient concerns in premature infants were of particular interest to my personal practice.

Discussions after the papers were presented have been included and often highlight areas of uncertainty or real practical importance.

Of course, in a book such as this there are going to be areas that don’t get covered, and, if you were looking for a comprehensive tome on this subject, then spending your money on a textbook might be better. But many of us purchase textbooks and then allow them to sit on the shelves collecting dust while we only “dip into” them occasionally. The good thing about this type of book is that you might actually end up reading some of it!

N Embleton
Consultant in Neonatal Medicine, Royal Victoria Infirmary, Newcastle upon Tyne, UK; n.d.embleton@ncl.ac.uk

LETTERS

Dehydration: the main cause of fever during the first week of life

We read with interest the findings of Maayan-Metzger et al on fever in healthy newborns during the first days of life.1

It is difficult to identify febrile neonates at low risk of serious bacterial infection.2 Although no consensus exists on the optimal approach to diagnosis and treatment, current guidelines recommend that febrile infants less than 28 days of age be admitted to hospital and given intravenous antibiotics for 48–72 hours. However, as mentioned in this report, dehydration is the primary cause of fever especially during the first days of life. We retrospectively reviewed the medical charts of patients admitted to our neonatal intensive care unit with fever between 1 May 1999 and 30 September 2003.

The inclusion criteria were gestational age >37 weeks, 1–7 days of postnatal age excluding the first day of life, axillary or rectal temperature >37.8°C on admission, normal physical examination with well appearance, no signs of focal infection, and no history of illness or antibiotics.

Overall, 46 febrile neonates were included in the study. Most (90–95%) were exclusively breast fed. Laboratory data included complete blood count, C reactive protein, serum urea and sodium concentrations, urinalysis, and blood, urine, and cerebrospinal fluid cultures. The mean (SD) duration of fever was 3.4 (1.9) days. The mean (SD) duration of fever was 2.8 (2.4) hours. Twenty seven infants (59%) had lost 8–24.3% of their birth weight. In 34 of the babies, white blood cell counts were between 5000 and 15 000/mm3. Serum sodium concentrations were obtained in 35 patients: mean (SD) was 147 (6.7) mmol/l and in 17 (40%) the levels were equal to or higher than 150 mmol/l. There was a positive correlation between weight and serum sodium concentration (p = 0.002). Mean (SD) serum urea nitrogen concentration was 19.3 (11.1) mmol/l. In 22 (48%) babies, serum bilirubin concentration was equal or greater than 220 mmol/l. Cultures were positive in seven babies. Coagulase negative staphylococci were recovered from five blood cultures and considered...
to be contaminated both clinically and in a negative repeated culture. In one infant, blood culture was positive for *Staphylococcus aureus*, and *Enterococcus* grew from culture of the urine in the other. Most admissions (83%) were between June and early October, which are the warmest months of the year in this area. In this low risk group of infants, only two patients had serious bacterial infection. Comparable with the findings of Maayan-Metzger et al., the results of our study dehydraly as the main cause of fever during the first week of life. As most of our cases occurred during summer and early autumn, environmental temperature may have an additive effect in this population.

F Tiker, B Gurakan, H Klicicag, A Tarcan
Faculty of Medicine, Baskent University, Ankara, Turkey; filiztiker@yahoo.com

DOI: 10.1136/adc.2003.047696

References


Increasing incidence of moderate neonatal hyperbilirubinemia in Wirral

Severe neonatal jaundice and bilirubin encephalopathy have been reported with increasing frequency from North America and Europe.1–3 There are no published reports of similar trends in Britain. We therefore examined trends in moderate neonatal hyperbilirubinemia in Wirral Hospital between 1991 and 2001. Neonates of ≥ 34 weeks gestation with a serum bilirubin of ≥ 340 μmol/l were identified from the laboratory database. Trends in hyperbilirubinemia were assessed using the χ² test for trend.

A total of 184 infants were identified; 122 presented before initial discharge, and 62 were readmissions. Median (interquartile range) gestational age was 38 (37–39) weeks, and 69% of affected infants were breast fed. The incidence of moderate jaundice increased from 2.4/1000 live births in 1991 to 5.5/1000 in 2001 (p < 0.0001). Despite a progressive fall in annual births, readmissions for jaundice increased from seven in the first six years of study to 55 in the second five years (p < 0.0001). Five infants needed exchange transfusion; all had haemolytic diseases. All were identified before initial discharge. No infants developed bilirubin encephalopathy, and none died.

Ours is the only report of recent trends in neonatal jaundice in Britain. Whether our experience is representative is not known, nor is the national incidence of bilirubin encephalopathy. These questions may be answered by a continuing study, supported by the British Paediatric Surveillance Unit, of severe neonatal jaundice.

F Walston, D Manning
Department of Paediatrics, Wirral Hospital, Merseysete CH49 5PE, UK; Rosselle@Yahoo.com

DOI: 10.1136/adc.2003.037242

References


Use of abbreviations in daily progress notes

Errors in medication and documentation are reported.1–4,7 These errors, no matter how minor, could have grave consequences for the patient, especially in the paediatric population. We therefore examined the potential threat to small neonates. Recently, Carroll et al. described problems in residents’ progress notes in a neonatal intensive care unit. Being the busiest centre in the country, managing the great majority of seriously sick neonates, we are at a very high risk of these errors. In view of this and as a screening audit, we looked at a few progress notes written on our inpatient neonates. One example of a progress note, written by a junior doctor, stated “Prem 32 WOG, F&G: Problems: RDS, IVH II, S/P SVT, Stable on RA, TPR normal, PU, BO, Chest, CVS & abdomen: NAD”. This excessive and inappropriate use of abbreviations is alarming and disturbing. The abbreviations used denoted the following (in order of citation): weeks of gestation, feeder and grower, respiratory distress syndrome, intraventricular grade 2 haemorrhage, status supraventricular tachycardia, room air, temperature pulse respiration, passed urine, bowel open, cardiovascular system, and no abnormality detected. This prompted us to look further into the incidence of abbreviations in the daily progress notes in our neonatal unit.

A cross section survey was carried out at the Special Care Baby Unit (SCBU), Royal Hospital, Muscat, on 7 October 2003. Thirty consecutive charts were reviewed. The progress notes written by seven different doctors (three registrars and four resident medical officers) were analysed for use of abbreviations. The commonly used ones were: CP (crystalline penicillin), RR (respiratory rate), HR (heart rate), BP (blood pressure), PA (per abdomen), O/E (on examination), NGT (nasogastric tube), UE1 (urea and electrolyte 1), BGA (blood gas analysis), BBA (born before arrival), TPN (total parenteral nutrition), SLS (standard liquid solution), STS (standard TPN solution), D/w (discussed with), SBR (serum bilirubin), CTG (cardiotocograph), IUGR (intrauterine growth restriction), IVH (intraventricular haemorrhage), ECHO (ultrasound), TAT (trans-anastomotic tube), IVF (intrauterine fluid or in vitro fertilisation), POD (postoperative day), ASD (atrial septal defect), VSD (ventricular septal defect), PDA (patent ductus arteriosus), TR (tricuspid regurgitation), L-R shunt (left to right shunt), TOF (tetralogy of Fallot), CRT (capillary refill time). One interesting note that needs separate mention was “Plan is to start ABs after aBc” (ABs, antibiotics; ABC, aerobic blood culture).

We noted a high frequency of the use of abbreviations in our neonatal unit. This was a single day observation; we would expect much more variability over a full medical study. Unfortunately, none of the abbreviations had resulted in erroneous interpretation, as most of the staff were used to them. However, this does not indicate that it is all right to use abbreviations. Standard abbreviations, such as VSD (ventricular septal defect) and PDA (patent ductus arteriosus), are acceptable, whereas others are not.

Documentation errors have been reported to be an increasing problem in day to day care of patients.1–4 A recent report described the same negligence in documentation by residents. Carroll et al. found discrepancies in the daily progress notes written by a resident doctor in the neonatal intensive care unit. They also found that notes often contained inaccurate information and lacked pertinent information. We looked further into the situation and found extensive use of abbreviations in progress notes.

Our observation is not unique and requires rectification. The solution could be to standardise or eliminate the use of abbreviations in the unit. Total elimination would be difficult, as many of the abbreviations are acceptable. Thus, the use of unacceptable abbreviations should be discouraged. New medical officers should be given brief instruction on the writing of appropriate progress notes. An alternative is to use the electronic information system for all medical transcription, including progress notes, as described elsewhere.7,12

In conclusion, care of neonates requires good documentation of day to day progress. The use of unacceptable abbreviations should be discouraged. A follow up audit is warranted to look further into the effect and success of our recommendations.

F Walston, D Manning
Department of Paediatrics, Wirral Hospital, Merseyside CH49 5PE, UK; Rosselle@Yahoo.com

References


Use of nasal continuous positive airway pressure during neonatal transfer

Within neonatal intensive care units, nasal continuous positive airway pressure (nCPAP)
What is the normal range of blood glucose concentration in healthy term newborns? The report by Dr Nicholl on ‘normal blood glucose concentrations in healthy term newborns’ raises the interesting and important question of how normoglycaemia in newborns can be defined. In a comprehensive review of the literature in 1997, an expert panel of the World Health Organization concluded that there are numerous approaches to defining normoglycaemia, including the statistical approach (which was taken by Dr Nicholl), the metabolic approach (what is the concentration of blood glucose at which normal cell homeostasis is maintained?), the neurophysiological approach (below what concentration of blood glucose does impairment of neurological functions occur?), and, perhaps most importantly, the neurodevelopmental approach (does a relation exist between neonatal blood glucose concentrations and the neurodevelopmental outcome of children years later?). These different approaches towards definition of normoglycaemia contribute to the controversy that surrounds this issue. Other factors that influence newborn blood glucose concentrations, even in healthy term newborns, are perinatal complications, mode of delivery, and feeding behaviour. It appears therefore that there is very little solid evidence on which judgment of neonatal blood glucose concentrations can be based. Follow up studies looking at neurodevelopmental outcome of neonatal ‘hypoglycaemia’ (and its treatment) in healthy term infants of various delivery modes and birth weights are urgently needed.

References
1 Nicholl OR. What is the normal range of blood glucose concentrations in healthy term newborns? Arch Dis Child 2003;88:238–9.

Gastric perforation and transillumination
We read with interest the article of Farrugia and colleagues about neonatal gastrointestinal perforation. However, there was no mention of:
- Isolated gastric perforation as a cause of neonatal gut perforation,
- Transillumination as a simple diagnostic tool of pneumoperitoneum.

We highlight these two points relating to a recent case. A 29 week gestation baby girl was born by vaginal delivery. She initially required conventional ventilation for her lung disease. An umbilical arterial catheter was inserted but removed after a few hours due to diskiness of the toes. On day 2 she was euvolaemic and nCPAP was tried. After a few hours, her condition deteriorated and she returned to conventional ventilation. On day 4, she was started on enteral feeding, using small volumes of breast milk, but had mild abdominal distension and some aspirates. Feeding was stopped. Her abdomen deteriorated and she had persistent metabolic acidosis. Transillumination of her abdomen was positive (fig 1) for pneumoperitoneum and was confirmed by abdominal x ray examination (fig 2). At laparotomy, two small gastric perforations were identified with local areas of infarction. These were oversewn, with excellent results.

Neonatal gastric perforation is unusual but serious. Various causative factors, including prematurity and nCPAP, have been suggested. Both of these were present in our case. It is also possible that emboli from the umbilical catheter led to small areas of infarction of the stomach wall.

Transillumination is a quick and easy technique for diagnosing pneumoperitoneum, and obviates the need for frequent radiographs.

References
Renal fungal ball

Preterm infants are prone to fungal infections because of immaturity of their host defence systems (immunology and skin). Other risk factors include multiple antibiotic therapy, prolonged use of umbilical or percutaneous catheters, total parenteral nutrition, colonisation and/or past mucocutaneous candidiasis, low birth weight, endotracheal tube placement, and congenital malformation.

Common sites for invasive candidiasis are the renal system, eyes, brain, and heart. Diagnostic tests should include blood and urine cultures, renal ultrasound, ophthalmological assessment, cardiac ultrasound, and examination of cerebrospinal fluid.

Candiduria may indicate colonisation, but the presence of other clinical signs increases the risk of invasive candidiasis. Fungal ball is the commonest presentation of renal fungal disease.

Clinical presentation may vary and can be obstructive, or non-obstructive, with renal failure.

A baby born at 28 weeks gestation was known to be colonised with Candida spp in the first weeks of life. The mother had declined routine antenatal care. The baby was ventilator dependent, with umbilical lines and received multiple broad spectrum antibiotics for possible bacterial sepsis.

After one month the baby developed thrombocytopenia and renal impairment. A renal ultrasound confirmed the presence of a solitary kidney with an echogenic mass.

Limited postmortem examination revealed multiple abscesses in the renal parenchyma, which grew Candida albicans only.

Invasive fungal infections in very low birthweight babies are currently the subject of a BPSU study (http://bpsu.inopsu.com/current.htm#Invasive).

REFERENCE


Figure 1 Solitary kidney with echodensities.

Figure 2 Gross pathology, showing multiple fungal abscesses.